| Date | Title | Description | |
|---|---|---|---|
| 08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
| 08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
| 25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
| 27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
| 27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
| 07 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |